Search Results
Your search for Matthew Stenger matches 581 pages
Showing 351 - 400EORTC Trial Shows Marginal Overall Survival and Significant Disease-Free Survival Benefit of Adding Regional Nodal Irradiation in Early Breast Cancer
In a phase III trial conducted by the European Organisation for Research and Treatment of Cancer (EORTC) Radiation Oncology and Breast Cancer Groups, the addition of regional nodal irradiation to whole-breast or thoracic-wall irradiation after surgery produced a marginal overall survival benefit...
Measurement of Intracellular and Extracellular Domain-Specific HER2 Expression May Predict Increased Benefit of Adjuvant Trastuzumab in Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Carvajal-Hausdorf et al found that quantitative measurement of HER2 protein expression in intracellular and extracellular domains indicated improved disease-free survival with adjuvant trastuzumab (Herceptin) in breast cancer ...
County-Based Analysis Suggests Widespread Overdiagnosis of Breast Cancer in Mammography Screening
In a study reported in JAMA Internal Medicine, Harding et al found that on the county level in the United States, mammography screening for breast cancer is associated with an increase in detection of small breast cancers but no reduction in breast cancer mortality. Study Details This ecologic...
Early Lapatinib and Trastuzumab Active in HER2-Positive Metastatic Breast Cancer
Lapatinib plus trastuzumab improves outcomes vs lapatinib in heavily pretreated HER2-positive metastatic breast cancer. In the phase II TBCRC 003 study reported in the Journal of Clinical Oncology, Lin et al found that earlier use of lapatinib plus trastuzumab was active in HER2-positive metastatic ...
Successful Preservation of Fertility After Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer
In a study reported in the Journal of Clinical Oncology, Oktay et al found that fertility could be preserved in women with breast cancer via embryo freezing after concurrent aromatase inhibitor treatment and ovarian stimulation. In the study, 131 women with stage ≤ III breast cancer underwent...
Meta-Analysis Indicates Benefit of Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer With Small Tumors
In a meta-analysis reported in the Journal of Clinical Oncology, O’Sullivan et al found that adjuvant trastuzumab (Herceptin) was associated with a significant disease-free and overall survival benefit among patients with early HER2-positive hormone receptor–positive and hormone...
Disparities in Use of Breast-Conserving Therapy for Early-Stage Breast Cancer
In a study using National Cancer Data Base data reported in JAMA Surgery, Lautner et al identified several factors associated with the use of breast-conserving therapy in women with early-stage breast cancer, including older age, higher education and income, private insurance, treatment at an...
Breastfeeding Associated With Reduced Risk of Breast Cancer Recurrence and Mortality in Luminal A Subtype
In a study reported in the Journal of the National Cancer Institute, Kwan et al found that women with basal-like tumors were less likely to have breastfed than those with luminal A tumors and that breastfeeding was associated with a significantly reduced risk of recurrence and breast...
Risk Factors for Interval Invasive Second Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Lee et al found that factors associated with an increased risk of interval second breast cancers after negative surveillance mammography included grade II primary breast cancer, lumpectomy without radiation, interval primary...
Better Outcome With Paclitaxel vs Nab-Paclitaxel or Ixabepilone Plus Bevacizumab in First-Line Treatment of Advanced Breast Cancer
In the phase III CALGB 40502/NCCTG N063H/Alliance trial reported in the Journal of Clinical Oncology, Rugo et al found that outcomes in first-line treatment for advanced breast cancer were better with weekly paclitaxel plus bevacizumab (Avastin) compared with weekly nanoparticle albumin-bound...
Survival Benefit of Surgery Lower for Low-Grade vs Higher-Grade Ductal Carcinoma in Situ
In a population-based cohort study reported in JAMA Surgery, Sagara et al found that the breast cancer–specific survival benefit associated with surgery for low-grade ductal carcinoma in situ is lower than that associated with surgery for intermediate- or high-grade ductal carcinoma in situ. ...
Differences in Patient-Reported Outcomes but Not Global Quality of Life With Exemestane vs Tamoxifen in Early Breast Cancer With Ovarian Suppression
In a pooled analysis of the TEXT and SOFT trials reported in The Lancet Oncology, Bernhard et al found no difference in global quality of life with exemestane vs tamoxifen in women with early breast cancer undergoing ovarian suppression. The two agents were associated with differences in specific...
Low Axillary Recurrence/Mortality Among Older Women With Node-Negative Breast Cancer Undergoing Breast-Conserving Surgery Without Sentinel Node Biopsy
In a single institution study reported in JAMA Surgery, Chung et al found a low axillary recurrence rate and low mortality among women with clinical T1–2N0 breast cancer aged ≥ 70 years who underwent breast-conserving surgery without sentinel node biopsy. Study Details The study involved ...
Four-Gene Model Predicts Response to Aromatase Inhibitor Therapy for Breast Cancer
As reported in the Journal of Clinical Oncology, Turnbull et al identified a four-gene predictive model of response to aromatase inhibitor therapy that was highly predictive of response on the basis of pretreatment and 2-week on-treatment measurements. The classifier was a significant predictor of...
Adding Everolimus to First-Line Trastuzumab-Paclitaxel Does Not Increase Progression-Free Survival in HER2-Positive Breast Cancer
In the phase III BOLERO-1 trial, reported in The Lancet Oncology, Hurvitz et al found that the addition of the mTOR inhibitor everolimus (Afinitor) to trastuzumab (Herceptin)-paclitaxel did not significantly increase progression-free survival among patients with HER2-positive advanced breast...
Long-Term Follow-Up of E1199 Trial Shows Maintained Benefit of Adjuvant Weekly Paclitaxel in Breast Cancer, Particularly Triple-Negative Disease
In long-term follow-up of the phase III E1199 trial reported in the Journal of Clinical Oncology by Sparano et al, adjuvant weekly paclitaxel and every-3-week docetaxel were associated with significantly longer disease-free survival and numerically longer overall survival vs every-3-week paclitaxel ...
Subset of Patients With Luminal A Breast Cancer May Not Benefit From Radiotherapy
In an analysis reported in the Journal of Clinical Oncology, Liu et al found that a subset of patients with luminal A breast cancer may not need radiotherapy to prevent relapse. Study Details The study involved samples from 501 older patients with node-negative disease who were randomized to...
Large Survival Disparity Within 2 Years of Diagnosis for Black vs White Women With ER-Positive Breast Cancer
In a study assessing factors in racial/ethnic survival disparities in breast cancer reported in the Journal of Clinical Oncology, Warner et al found that black women with estrogen receptor (ER)-positive breast cancer were significantly more likely to die from the disease within the first 2 years of ...
Denosumab Reduces Clinical Fracture Risk in Postmenopausal Women Receiving Aromatase Inhibitors
In a phase III trial (ABCSG-18) reported in The Lancet, Gnant et al found that adjuvant denosumab (Xgeva) reduced the risk of clinical fracture in women with breast cancer receiving aromatase inhibitor therapy. Study Details In the double-blind study, 3,420 women from Austria and Sweden with...
Palbociclib Improves Progression-Free Survival in Advanced Hormone Receptor–Positive Breast Cancer
In a phase III PALOMA 3 trial reported at the 2015 ASCO Annual Meeting and published in The New England Journal of Medicine, Turner et al found that the cyclin-dependent kinase 4 and 6 inhibitor palbociclib (Ibrance) significantly improved progression-free survival in women with advanced hormone...
Swedish Study Identifies Predictors of Discontinuing Adjuvant Hormone Therapy for Breast Cancer
In a Swedish study reported in the Journal of Clinical Oncology, He et al identified numerous predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. Study Details The study involved 3,395 women diagnosed with breast cancer between 2005 and 2008 in Stockholm who...
Higher Tumor-Infiltrating Lymphocyte Level Associated With Better Outcomes in HER2-Positive Early Breast Cancer Independent of Neoadjuvant Treatment
In an analysis of the NeoALTTO trial reported in JAMA Oncology, Salgado et al found that a higher level of tumor-infiltrating lymphocytes was associated with improved pathologic compete response rate and event-free survival independent of neoadjuvant treatment received in patients with...
Addition of Number of Metastases Improves Prognostic Assessment Tool in Breast Cancer With Brain Metastases
As reported in the Journal of Clinical Oncology by Subbiah et al, the addition of number of brain metastases to the breast graded prognostic assessment (breast-GPA) tool improved the prediction of overall survival in breast cancer patients with brain metastases. The existing breast-GPA includes...
Breast Cancer Subtype Incidence in the United States for 2011
The current annual report of cancer statistics by the American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries includes a focus on breast cancer incidence by subtype using new national-level data. The ...
Minority of Medicare Patients Have Adequate Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Chavez-MacGregor et al found that the majority of older breast cancer patients receiving trastuzumab (Herceptin)-based chemotherapy do not receive adequate cardiac monitoring. Study Details The study involved 2,203 patients aged ≥...
Polish Study Shows Inherited PALB2 Mutation Confers Greater Risk and Poorer Outcome of Breast Cancer
In a Polish prospective cohort analysis reported in The Lancet Oncology, Cybulski et al found that PALB2 mutation carriers had increased risk of breast cancer and that those with breast cancer had significantly reduced long-term survival. Study Details In the study, genotyping for two...
Omega-3 Fatty Acids and Placebo Reduce Aromatase Inhibitor–Related Musculoskeletal Pain in Early Breast Cancer
In the SWOG S0927 trial reported in the Journal of Clinical Oncology, Hershman et al found that both omega-3 fatty acids and placebo resulted in marked persistent reductions in aromatase inhibitor–related arthralgia among patients with early breast cancer, with no difference between...
Improved Pathologic Complete Response Rate With Addition of Bevacizumab to Neoadjuvant Therapy in HER2-Negative Early Breast Cancer
In the phase III ARTemis trial reported in The Lancet Oncology, Earl et al found that the addition of bevacizumab (Avastin) to standard neoadjuvant therapy resulted in a higher pathologic complete response rate in women with HER2-negative early breast cancer. Study Details In this open-label...
Physical Activity Programs Produce Benefits in Patients Receiving Adjuvant Therapy for Breast Cancer
In the Dutch PACES trial reported in the Journal of Clinical Oncology, van Waart et al found that both a moderate/high-intensity supervised exercise program and a low-intensity home-based program provided benefits vs usual care in women undergoing adjuvant chemotherapy for breast cancer. Benefits,...
Dutch Analysis Questions Breast Cancer Protective Effect of Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers
In a Dutch study reported in the Journal of the National Cancer Institute, Heemskerk-Gerritsen et al in the Hereditary Breast and Ovarian Cancer in the Netherlands (HEBON) study group found no apparent reduction in the risk for breast cancer with salpingo-oophorectomy in healthy BRCA1/2 mutation...
CEP17 or TOP2A Aberrations Predict Benefit of Adjuvant Anthracycline-Based Chemotherapy in Breast Cancer
In a study reported in the Journal of Clinical Oncology, Bartlett et al found that the presence of duplication of chromosome 17 pericentromeric alpha satellite, measured by a centromere enumeration probe (CEP17), and TOP2A aberrations predicted benefit of anthracycline-based adjuvant therapy in...
Hospital and Surgeon Factors Associated With Axillary Lymph Node Evaluation in DCIS
In a study reported in JAMA Oncology, Coromilas et al found that axillary lymph node evaluation is frequently performed in women with ductal carcinoma in situ (DCIS), and a number of hospital or surgeon characteristics are associated with likelihood of evaluation. As noted by the authors, benefit...
Oophorectomy Is Associated With Significantly Reduced Breast Cancer Mortality in Patients With BRCA1 Mutation or Estrogen Receptor–Negative Disease
In a retrospective analysis reported in JAMA Oncology, Metcalfe et al found that oophorectomy in patients with early-stage breast cancer was associated with significantly improved breast cancer survival in women harboring a BRCA1 mutation and in those with estrogen receptor–negative...
Differing Patterns of Breast Cancer Risk After Hormone Therapy With Estrogen Plus Progestin or Estrogen Alone
In an analysis of Women’s Health Initiative (WHI) trials reported in JAMA Oncology, Chlebowski et al found differing patterns of breast cancer risk among women receiving menopausal hormone therapy with estrogen plus progestin or estrogen alone. Women receiving estrogen plus progestin had...
Association of Lipid Levels With Breast Cancer Risk in Women With Extensive Mammographic Density
In a nested case-control study reported in Journal of the National Cancer Institute, Martin et al found that higher HDL cholesterol and apolipoprotein A1 (apoA1) levels and lower non-HDL cholesterol and apolipoprotein B (apoB) levels were associated with increased risk of breast cancer in women...
Glembatumumab Vedotin Appears Active in Heavily Treated Advanced Glycoprotein NMB–Overexpressing Breast Cancer and Triple-Negative Disease
In the randomized phase II EMERGE study reported in the Journal of Clinical Oncology, Yardley et al found that the anti–glycoprotein NMB (gpNMB) antibody-drug conjugate glembatumumab vedotin may improve response rate over alternative chemotherapy in patients with advanced refractory breast...
Regional-Level Correlation of Inappropriate Prostate Imaging and Inappropriate Breast Imaging
In a study reported in JAMA Oncology, Makarov et al found that hospital referral regions marked by higher rates of inappropriate imaging in patients with low-risk breast cancer also had high rates of inappropriate prostate imaging in patients with low-risk prostate cancer. Inappropriate imaging...
Platinum Monotherapy Particularly Active in BRCA1/2-Mutant Metastatic Triple-Negative Breast Cancer
In the phase II TBCRC009 trial reported in the Journal of Clinical Oncology, Isakoff et al found that platinum monotherapy was active in treatment of metastatic triple-negative breast cancer, particularly in cases with BRCA1/2 mutation, and that an assay of genomic instability characteristic of...
Neoadjuvant Iniparib Plus Gemcitabine-Carboplatin Is Active in Early Triple-Negative and BRCA1/2-Mutant Breast Cancer
In the phase II PrECOG 0105 study reported in the Journal of Clinical Oncology, Telli et al found that neoadjuvant iniparib plus gemcitabine-carboplatin was active in early-stage triple-negative and BRCA1/2-mutant breast cancer. Higher score on a homologous recombination deficiency–loss of...
Worse Outcomes With Lapatinib vs Trastuzumab Plus Taxane in Advanced HER2-Positive Breast Cancer
In the phase III National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) MA.31 trial, first-line treatment with lapatinib (Tykerb) vs trastuzumab (Herceptin) combined with a taxane was associated with poorer progression-free survival and greater toxicity in patients with advanced...
Substantial Pathologist Diagnostic Disagreement for Breast Biopsy Specimens
In a study reported in JAMA, Elmore et al found a substantial rate of disagreement between pathologist diagnosis based on single breast biopsy slides and the consensus-derived diagnosis of a panel of pathologists. Disagreement rates were highest for ductal carcinoma in situ (DCIS) and atypical...
Italian Trial Shows Benefit of Dose-Dense Adjuvant Therapy With Sequential Epirubicin-Cyclophosphamide-Paclitaxel in Early Node-Positive Breast Cancer
In an Italian 2×2 phase III trial reported in The Lancet, Del Mastro et al found that dose-dense adjuvant therapy with sequential epirubicin, cyclophosphamide, and paclitaxel (EC-P) with or without fluorouracil (5-FU) increased disease-free survival vs standard-interval therapy in early-stage ...
Insufficient Awareness of Breast Density and Its Impact on Breast Cancer Detection and Risk
In a study reported in the Journal of Clinical Oncology, Rhodes et al found that only about half of screening-age women had awareness of breast density and adequate knowledge of its impact on breast cancer detection and risk. Breast density is an important factor contributing to false-negative...
Goserelin Provides Ovarian Protection During Adjuvant Chemotherapy for Breast Cancer
In the phase III POEMS/S0230 trial reported in The New England Journal of Medicine, Moore et al found that treatment with the gonadotropin-releasing hormone agonist goserelin (Zoladex) reduced risk of ovarian failure during chemotherapy for breast cancer in premenopausal women. Study Details In...
Reduced Mammography Rates 3 Years After 2009 U.S. Preventive Services Task Force Guidelines Changes
In a study reported in the Journal of Clinical Oncology, Wharam et al found that estimated mammography rates were lower than predicted in white, Hispanic, and Asian women since the U.S. Preventive Services Task Force (USPSTF) changed its screening recommendations in November 2009. The guidelines...
MRI Screening More Sensitive Than Mammography and Ultrasound for Familial Breast Cancer Irrespective of Age, Mutation Status, or Breast Density
In a single-center study reported in the Journal of Clinical Oncology, Riedl et al found that screening with magnetic resonance imaging (MRI) had greater sensitivity for detection of breast cancer in high-risk women vs mammography or ultrasound irrespective of age, mutation status, or breast...
Immunologic Factors Predict Pathologic Complete Response to Neoadjuvant Therapy With or Without Carboplatin in Breast Cancer
In a study reported in the Journal of Clinical Oncology, Denkert et al found that increased tumor-infiltrating lymphocytes and the presence of lymphocyte-predominant breast cancer were associated with increased rates of pathologic complete response in patients receiving neoadjuvant...
Acceptable Cardiac Safety of Ado-Trastuzumab Emtansine After Anthracycline-Based Chemotherapy in Early-Stage HER2-Positive Breast Cancer
In a study reported in the Journal of Clinical Oncology, Krop et al found that ado-trastuzumab emtansine (Kadcyla) had an acceptable cardiac safety profile when used after anthracycline-based (neo)adjuvant therapy in women with early-stage HER2-positive breast cancer. Study Details In the study,...
Lower Household Net Worth and Black Race Associated With Nonadherence to Hormonal Therapy for Early-Stage Breast Cancer
In a study reported in the Journal of Clinical Oncology, Hershman et al found that nonadherence to adjuvant hormonal therapy for early-stage breast cancer was more common among black women and patients with lower household net worth, with the latter factor partly accounting for the racial...
Aurora Kinase A Inhibitor Alisertib Active in Solid Tumors
In a phase II study reported in The Lancet Oncology, Melichar et al found that the oral aurora kinase A inhibitor alisertib was active in solid tumors, particularly breast cancer and small cell lung cancer. Aurora kinases play central roles in mitosis. Inhibition of aurora kinase A, which is...
